The 22 analysts offering 12-month price forecasts for Vertex Pharmaceuticals Inc have a median target of 279.00, with a high estimate of 358.00 and a low estimate of 250.00. The median estimate represents a +29.42% increase from the last price of 215.57.
The current consensus among 26 polled investment analysts is to Buy stock in Vertex Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $2.21
Reporting Date Jul 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.